MAGICAL MEDICINE: HOW TO MAKE AN ILLNESS ... - Invest in ME
MAGICAL MEDICINE: HOW TO MAKE AN ILLNESS ... - Invest in ME
MAGICAL MEDICINE: HOW TO MAKE AN ILLNESS ... - Invest in ME
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
409<br />
APPENDIX I: Dr Tony Johnson, Deputy Director of the MRC Biostatistical Unit, Cambridge<br />
The UK <strong>ME</strong>/CFS community noted with some surprise the <strong>in</strong>volvement of Dr Tony Johnson <strong>in</strong> the PACE<br />
Trial because his published views on psychiatric trials are already known. In 1998 he published a major<br />
review entitled “Cl<strong>in</strong>ical trials <strong>in</strong> psychiatry: background and statistical perspective” (Statistical Methods <strong>in</strong><br />
Medical Research 1998:7:209‐234) <strong>in</strong> which he noted the existence of studies produced by psychiatrists that<br />
claim “<strong>in</strong>ord<strong>in</strong>ate enthusiasm” for certa<strong>in</strong> therapies.<br />
Dr Tony Johnson is the son‐<strong>in</strong>‐law of Dr Elizabeth Dowsett, who was formerly Medical Advisor to and<br />
President of the <strong>ME</strong> Association. Correspondence exists between an <strong>ME</strong>/CFS sufferer and Dr Johnson<br />
himself, but which also <strong>in</strong>volves Dr Anthony C Peatfield, Head of MRC Corporate Governance and Policy.<br />
The correspondence arose from Johnson’s Qu<strong>in</strong>quennial Report for the MRC’s Biostatistical Unit’s progress<br />
report for the years 2001 to 2006 that was placed on the website of the MRC Biostatistics Unit (BSU).<br />
Taken from the BSU’s Qu<strong>in</strong>quennial Review of 2006, one part of which states: “Our <strong>in</strong>fluence on policy‐<br />
makers has largely been <strong>in</strong>direct, through scientistsʹ work on advisory committees, <strong>in</strong> lead<strong>in</strong>g editorials, <strong>in</strong><br />
personal correspondence with M<strong>in</strong>isters, Chairs or Chief Executives (such as of Healthcare Commission or<br />
NICE), Chief Medical Officers and Chief Scientific Advisers, or through public dissem<strong>in</strong>ation when the<br />
media picks up on statistical or public health issues that our publications have highlighted.<br />
“The Unitʹs scientists must rema<strong>in</strong> wary of patient‐pressure groups. Tony Johnsonʹs work on chronic fatigue<br />
syndrome (CFS), a most controversial area of medical research, has had to counter vitriolic articles and<br />
websites ma<strong>in</strong>ta<strong>in</strong>ed by the more extreme charities and supported by some patient groups, journalists,<br />
Members of Parliament, and others, who have little time for research <strong>in</strong>vestigations”.<br />
This contention that “CFS” research is beset with vitriol and “extreme” charities was re‐iterated by Johnson<br />
himself <strong>in</strong> his own Report with<strong>in</strong> the Qu<strong>in</strong>quennial Review; under “Chronic Fatigue Syndrome (CFS), with<br />
P White, T Chalder (London), M Sharpe (Ed<strong>in</strong>burgh)”, Johnson’s Report stated:<br />
“CFS is currently the most controversial area of medical research and characterised by vitriolic articles and websites<br />
ma<strong>in</strong>ta<strong>in</strong>ed by the more extreme charities supported by some patient groups, journalists, Members of Parliament, and<br />
others, who have little time for research <strong>in</strong>vestigations. In response to a DH (Department of Health) Directive, MRC<br />
called for grant proposals for <strong>in</strong>vestigations <strong>in</strong>to CFS as a result of which two RCTs (PACE and FINE) were funded<br />
and have started despite active campaigns to halt them. I am part of the PACE study, a multi‐centre study compar<strong>in</strong>g<br />
cognitive behaviour therapy, graded exercise tra<strong>in</strong><strong>in</strong>g, and pac<strong>in</strong>g <strong>in</strong> addition to standardised specialist medical care<br />
(SSMC), with SSMC alone <strong>in</strong> 600 patients. I have been fully engaged <strong>in</strong> provid<strong>in</strong>g advice about design of PACE and I<br />
am a member of both Trial Management Group and Trial Steer<strong>in</strong>g Committee. I am not a PI (Pr<strong>in</strong>cipal <strong>Invest</strong>igator)<br />
because of familial <strong>in</strong>volvement with one of the charities, a perspective that has enabled me to play a vital role <strong>in</strong><br />
ensur<strong>in</strong>g that all <strong>in</strong>volved <strong>in</strong> the PACE trial ma<strong>in</strong>ta<strong>in</strong> absolute neutrality to all trial treatments <strong>in</strong> presentation,<br />
documentation and assessment”.<br />
Johnson’s Report on “CFS” research rang alarm bells with<strong>in</strong> the <strong>ME</strong>/CFS community, s<strong>in</strong>ce it openly stated<br />
that he, personally, had a “vital” role to play <strong>in</strong> ensur<strong>in</strong>g what ought to have been taken for granted <strong>in</strong> any<br />
MRC trial, namely the “absolute neutrality” of the PACE trial.<br />
Upon see<strong>in</strong>g this on the MRC Biostatistics Unit’s (BSU) website, an <strong>ME</strong>/CFS sufferer wrote first to the MRC<br />
Biostatistics Unit and then to Dr Johnson himself, request<strong>in</strong>g the names and details of all the charities,<br />
patient groups, journalists, Members of Parliament and “others” who have little time for research<br />
<strong>in</strong>vestigations, together with references for all the vitriolic articles and websites mentioned on the MRC BSU<br />
website.